Institute of Cancer Research: ESMO 2020 - Breast Cancer Drug Set to Transform Prostate Cancer Treatment
September 21, 2020
September 21, 2020
LONDON, England, Sept. 21 (TNSJou) -- The Institute of Cancer Research issued the following news release:
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.
Final results from the trial showed that olaparib - a pioneering type of drug called a PARP inhibitor and the first ever cancer drug to targe . . .
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.
Final results from the trial showed that olaparib - a pioneering type of drug called a PARP inhibitor and the first ever cancer drug to targe . . .